Implantica Expands Reach with 15th RefluxStop™ Center Opening in Spain

Implantica AG, a leading medtech company specializing in advanced solutions for medical needs, has announced the establishment of its 15th RefluxStop™ Center. This new center, located at the Hospital Universitario Central de Asturias in Oviedo, Spain, is set to provide groundbreaking treatment options for patients suffering from gastroesophageal reflux disease (GERD) — a condition affecting approximately one billion people worldwide.

A New Hope for GERD Patients

The recent opening of the RefluxStop™ Center marks a significant milestone in the treatment of acid reflux. The RefluxStop™ device offers a novel solution that addresses the root causes of GERD without the complications associated with traditional surgical methods. Dr. Maria Moreno Gijón, a distinguished surgeon at the hospital, performed the inaugural procedures with this innovative device.

Dr. Moreno Gijón expressed her enthusiasm for the RefluxStop™ treatment, stating, “For years, I have sought a new surgical option for treating GERD. Many patients have lost hope after unsatisfactory results from current treatments. The RefluxStop™ finally provides a viable solution for all GERD patients, significantly impacting their quality of life.”

Revolutioanry Treatment Approach

The RefluxStop™ device sets itself apart by not encircling the esophagus, which is a common drawback of existing surgical approaches. Traditional surgeries often lead to severe side effects, including difficulties in swallowing and the inability to belch or vomit. In contrast, the RefluxStop™ treats acid reflux by restoring the lower esophageal sphincter’s function without placing undue pressure on it, thereby maintaining the body's natural anatomical position. This unique approach aims to resolve issues associated with GERD effectively and safely.

Dr. Peter Forsell, CEO and founder of Implantica, emphasized the swift adoption of the RefluxStop™ procedure among leading Spanish surgeons, expressing his gratitude for the collaboration. He said, “It’s truly impressive to see fifteen centers of excellence established in Spain within just two years since the launch of RefluxStop™. This growth reflects the high demand for our revolutionary treatment.”

Addressing a Significant Medical Need

Research indicates that up to 40% of GERD patients do not respond well to proton pump inhibitors (PPIs), which are the primary medical management strategy for this condition. Many of these patients are not suitable candidates for standard anti-reflux surgeries, leaving them to endure painful symptoms due to acid regurgitation. The RefluxStop™ offers these patients renewed hope, providing an alternative that can improve their quality of life.

Dr. Forsell added, “The RefluxStop™ centers, including the new location in Oviedo, allow us to reach more patients with innovative surgical solutions for GERD. We are optimistic that this will bring relief to countless individuals suffering from this debilitating condition.”

Conclusion

The opening of the 15th RefluxStop™ Center at Hospital Universitario Central de Asturias represents a significant development in the field of anti-reflux surgery. By offering this advanced treatment, Implantica continues to pave the way for improved solutions for GERD patients. The initiative showcases the potential to make a lasting difference in healthcare, reaffirming Implantica's commitment to enhancing patient outcomes through innovative medical technology.

For further information about Implantica and the RefluxStop™ device, please visit Implantica's official website.